GDTC
CytoMed Therapeutics Limited
stockNASDAQ
incorporated in 2018, cytomed therapeutics is a spin-off from singapore's agency for science, technology and research ( a*star) and focuses on translating its patented technologies into gamma delta (γδ) t cell- and natural killer (nk) cell-based "off-the-shelf" immunotherapeutics for a wide range of cancers. we also engage in generating induced pluripotent stem cells (ipscs) and translating them into "off-the-shelf" cellular therapeutics using our proprietary technologies for our customers.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.93 | 2026-10-26 | -0.67% | -0.837 |
| 3M | 0.92 | 2026-08-03 | +0.09% | -0.540 |
| 6M | 0.97 | 2026-05-01 | -5.50% | -0.180 |
| 1Y | 2.12 | 2025-11-03 | -56.50% | 0.094 |
| 2Y | 2.31 | 2024-11-01 | -60.09% | — |
| 5Y | 4.00 | 2023-04-14 | -77.00% | -0.005 |
CytoMed Therapeutics Limited (NASDAQ:GDTC) stock price today is $0.92, and today's volume is 42,708. GDTC is up 0.131% today. The 30 day average volume is 17,770. GDTC market cap is $10.98M with 11.93M shares outstanding.